The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805).
Chigusa Morizane
Honoraria - Novartis
Takuji Okusaka
Honoraria - Lilly; Taiho Pharmaceutical
Research Funding - Lilly; Taiho Pharmaceutical
Junki Mizusawa
No relevant relationships to disclose
Atsuo Takashima
No relevant relationships to disclose
Makoto Ueno
No relevant relationships to disclose
Masafumi Ikeda
No relevant relationships to disclose
Yasuo Hamamoto
No relevant relationships to disclose
Hiroshi Ishii
Honoraria - Lilly
Narikazu Boku
No relevant relationships to disclose
Junji Furuse
Consultant or Advisory Role - Bayer; Chugai Pharma; Eisai
Honoraria - Bayer; Lilly; Taiho Pharmaceutical